Etoposide by oral route in the treatment of unresectable non-small cell lung cancer.
Twenty patients with unresectable non-small cell lung cancer (10 squamous cell carcinoma, 7 adenocarcinoma, 3 large cell carcinoma), previously untreated, received etoposide 300 mg/m2 by oral route days 1-3-5 every three weeks. No complete or partial remissions were observed but only two minor responses. There were 7 stable diseases and 11 progressive diseases. Myelosuppression activity was usually mild and gastro-intestinal side effects were the most prominent. In this trial etoposide by oral route has shown only marginal activity against non-small cell lung cancer.
D000284:Administration, Oral; D000368:Aged; D005047:Etoposide / Q000008:administration & dosage* / Q000009:adverse effects / Q000378:metabolism; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011034:Podophyllotoxin / Q000031:analogs & derivatives*
D005047:Etoposide; D011034:Podophyllotoxin